Lenvatinib
- PDF / 169,904 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 42 Downloads / 154 Views
1
S
Myelosuppression: case report A 76-year-old man developed myelosuppression during treatment with lenvatinib for anaplastic thyroid carcinoma. The man presented to hospital with bulky cervical tumour mass and apparent disseminated maculopapular eruptions on his trunk and limbs. His blood smear showed severe neutrophilia and eosinophilia. Based on initial examinations a suspicious diagnosis of drug eruption was made and his ongoing treatment with paracetamol [acetaminophen] and zolpidem [zolpidem tartrate] was discontinued. In spite of discontinuation of treatment, his rash further deteriorated. He received further treatment with methylprednisolone and prednisolone, but there was no alleviation in his condition. The prednisolone treatment was continued with reduced dose. On further examination, he was diagnosed with anaplastic thyroid carcinoma. Therefore, he started receiving treatment with oral lenvatinib [lenvatinib mesilate] 24mg daily. Subsequently, his neutrophil count declined and improvement in the rash was noted. However, during treatment, he developed myelosuppression [duration of treatment to reaction onset not stated]. The man’s treatment with lenvatinib was discontinued. Despite discontinuation of lenvatinib, myelosuppression continued. Recurrence of rash was not observed. Eventually, five weeks after lenvatinib administration, he died due to tumour progression. Author comment: "The lenvatinib successfully decreased the size of the tumor. However, its myelosuppressive adverse effect made us discontinue administration." Kasuya A, et al. Intractable disseminated maculopapular eruption in a patient with granulocyte macrophage colony-stimulating factor-producing anaplastic thyroid carcinoma. Journal of Dermatology 46: e432-e433, No. 11, Nov 2019. Available 803437142 from: URL: http://doi.org/10.1111/1346-8138.14950 - Japan
0114-9954/19/1781-0001/$14.95 Adis © 2019 Springer Nature Switzerland AG. All rights reserved
Reactions 30 Nov 2019 No. 1781
Data Loading...
